All In Biotech

Drug Trial Radar · NCT04615949

Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors

Study to Evaluate the Efficacy and Safety of CardiolRx™ in Patients With COVID-19 and Cardiovascular Disease or Risk Factors A Double-blind, Placebo-controlled Trial

Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

90

Actual

Start

Apr 30, 2021

Primary completion

Nov 30, 2022

Study completion Nov 30, 2022

Sponsor

Lead sponsor
Cardiol Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Nov 4, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Non-critical patients, hospitalized within the previous 24 hours who tested positive for COVID-19 and have a prior history of cardiovascular disease (CVD) and/or significant risk factors for CVD will be treated for 28 days.

Conditions

  • COVID-19
  • Cardiovascular Diseases
  • Cardiovascular Risk Factor

Interventions

  • Cannabidiol, pharmaceutically produced with < 5 ppm THCDrug

    CardiolRx 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food

  • PlaceboDrug

    Placebo 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of All-cause Mortality, Requirement for ICU Admission and/or Ventillatory Support and Cardiovascular ComplicationsTime frame: 28 days post randomization

Locations

20 sites in 3 countries. Site status is shown where the registry gives one.

  • Valleywise Health Medical Center

    Phoenix, Arizona

  • JY Research Institute

    Cutler Bay, Florida

  • Westchester General Hospital

    Miami, Florida

  • University of South Florida

    Tampa, Florida

  • Prairie Education and Research Cooperative

    Springfield, Illinois

  • University of Texas Health Science Center

    San Antonio, Texas

  • Baylor Scott & White Health - Temple

    Temple, Texas

  • Complexo Hospitalar de Niteroi- Centro de Pesquisa Clinica

    Rio de Janeiro, Brazil

  • Science Valley Research Institute

    Campo Largo, Paraná, Brazil

  • Universidade Estadual de Maringa

    Maringá, Paraná, Brazil

  • Hospital São Lucas PUCRS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Irmandade Santa Casa de Misericórdia

    Porto Alegre, Rio Grande do Sul, Brazil

  • Núcleo de Ensino e Pesquisa do Instituto Mário Penna

    Conjunto ACM, Santa Maria, Brazil

  • Fundação Pio XII - Hospital de Amor Barretos

    Barretos, São Paulo, Brazil

  • IPECC-Instituto de Pesquisa Clínica de Campinas

    Campinas, São Paulo, Brazil

  • Instituto do Coração do HCFMUSP

    Cerqueira César, São Paulo, Brazil

  • SVRI- Irmandade de Santa Casa de Misercordia de Santos

    Jabaquara, São Paulo, Brazil

  • Science Valley Research Institute

    Santo André, São Paulo, Brazil

  • Fundação Faculdade Regional de Medicine de Sao Jose do Rio Preto (SJRP)

    São José do Rio Preto, São Paulo, Brazil

  • TecSalud

    Monterrey, Nuevo León, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.